Otsuka changes tack in Abilify patent case after landmark Wyeth ruling
Allens 2019-09-11 8:49 pm | Sydney
Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last year against Wyeth that clarified the issue of compensation under the usual undertaking for damages in pharmaceutical patent cases.
For information on rights and reprints, contact subscriptions@lawyerly.com.au